Welcome to our dedicated page for Rf Acquisition Ii news (Ticker: RFAI), a resource for investors and traders seeking the latest updates and insights on Rf Acquisition Ii stock.
RF Acquisition Corp II (NASDAQ: RFAI) is a blank check company and SPAC focused on completing a business combination with one or more businesses, with an emphasis on deep technology targets in Asia. News related to RFAI often centers on its capital markets activity, shareholder votes, and progress toward identifying and executing a qualifying transaction.
A key development for RF Acquisition Corp II is its Business Combination Agreement with Nanyang Biologics Pte. Ltd., an AI‑driven drug discovery and biotechnology company. Public announcements describe a transaction under which RF Acquisition Corp II will merge with a Cayman Islands holding company and Nanyang Biologics will become a wholly owned subsidiary of that holding company. Coverage of this proposed transaction includes details on the planned listing of the combined company, the agreed structure of the merger and amalgamation, and the role of RF Acquisition Corp II’s shareholders in approving the deal.
Investors following RFAI news can expect updates on:
• Transaction milestones: announcements about the signing of the Business Combination Agreement, filing of registration statements, proxy materials, and any amendments or supplemental disclosures.
• Shareholder meetings and votes: notices and results of extraordinary general meetings, including votes on extending the business combination deadline and approving transaction‑related proposals.
• Trust account and redemptions: reports on redemptions of public shares, remaining funds in the trust account, and any extensions of the combination period under the trust agreement.
This news page aggregates company press releases, partner announcements, and SEC‑related news so that readers can monitor how RF Acquisition Corp II advances its proposed combination with Nanyang Biologics and manages its SPAC lifecycle. For investors and observers of SPAC transactions, the RFAI news feed provides a centralized view of corporate actions, transaction progress, and key shareholder decisions.
Nanyang Biologics (NASDAQ:RFAI) has announced a $1.5 billion business combination agreement with RF Acquisition Corp II to become publicly listed under ticker "NYB". The company operates an AI-driven drug discovery platform with its flagship Vecura™ AI platform powered by proprietary DTIGN technology, which outperformed competitors by 27% in 2024 benchmarking tests.
NYB's leading candidate, NB-A002, is a first-in-class oncology therapy targeting the undruggable ILF2 protein, positioned to address the $19.5 billion DDR therapy market by 2030s. The company has established a strategic joint laboratory with Nanyang Technological University Singapore (NTU) and collaborates with major tech partners including NVIDIA, HP, and Equinix.
The transaction is expected to close in Q1/Q2 2026, with existing shareholders retaining majority ownership and board control.
The9 Limited (Nasdaq: NCTY) announced that its Singapore investee Nanyang Biologics (NYB) will merge with RF Acquisition Corp II (NASDAQ: RFAI) in a $1.5 billion SPAC deal. The combined company will list on Nasdaq under ticker "NYB" in Q1-Q2 2026.
NYB, winner of the SuperAI Genesis Startup Competition 2025, has partnered with Nvidia, HP Enterprise, and Equinix to build the world's largest natural compound library for AI drug discovery. The company's lead candidate, NB-A002, has shown promising preclinical results as the first therapy targeting ILF2 for cancer treatment.
The company's proprietary DTIGN platform has mapped extensive molecules and maintains a diverse living library of over 50,000 unique organisms and their chemical compounds for drug development.
RF Acquisition Corp. (RFAC), a blank check company based in Singapore, has announced an updated per-share redemption price of approximately $11.24 for its public shares. This announcement comes ahead of the special meeting of stockholders scheduled for September 23, 2024. The redemption price aligns with the closing price of RFAC's Class A Common Stock on September 13, 2024.
RFAC, incorporated in 2021, aims to effect a business combination with one or more businesses, focusing on the Southeast Asian new economy sector or other global targets. The company's primary purpose is to pursue mergers, capital stock exchanges, asset acquisitions, stock purchases, reorganizations, or similar business combinations.
RF Acquisition Corp II (NASDAQ: RFAIU) announced that starting July 5, 2024, holders of the 11,500,000 units sold in its initial public offering can choose to trade the ordinary shares and rights separately. Units not separated will continue to trade under the symbol 'RFAIU,' while the separated shares and rights will trade under 'RFAI' and 'RFAIR,' respectively. To separate units, unitholders must have their brokers contact Continental Stock Transfer & Trust Company. EarlyBirdCapital, Inc. managed the offering, which was made by prospectus after being declared effective by the SEC on May 16, 2024. Copies of the prospectus can be obtained from EarlyBirdCapital, Inc.
RF Acquisition Corp II announced the closing of its $100 million initial public offering (IPO) on May 21, 2024. The IPO involved 10,000,000 units priced at $10.00 per unit, listed on the Nasdaq Global Market under the ticker symbol 'RFAIU' as of May 17, 2024. Each unit includes one ordinary share and one right to receive one-twentieth of an ordinary share. The company, a blank check entity, aims to merge or acquire one or more businesses but has not yet identified any targets. EarlyBirdCapital, Inc. is the sole bookrunning manager, with Revere Securities as the co-manager.
FAQ
What is the current stock price of Rf Acquisition Ii (RFAI)?
What is the market cap of Rf Acquisition Ii (RFAI)?
